A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
City of Hope Medical Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
ImmunityBio, Inc.
University of Southern California
Trishula Therapeutics, Inc.
German Cancer Research Center
University Hospital, Geneva
OHSU Knight Cancer Institute
Sumitomo Pharma America, Inc.
Georgetown University
University of Chicago
Roswell Park Cancer Institute
Washington University School of Medicine
H. Lee Moffitt Cancer Center and Research Institute
Benaroya Research Institute
Roswell Park Cancer Institute
University of California, San Francisco